M

Mersana Therapeutics
D

MRSN

0.29380
USD
0.01
(4.56%)
مغلق
حجم التداول
27,349
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
36,616,687
أصول ذات صلة
AMGN
AMGN
1.79
(0.60%)
298.52 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
N
NKTR
-0.740
(-2.90%)
24.775 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.